Last reviewed · How we verify
Budesonide Inhalant Product
At a glance
| Generic name | Budesonide Inhalant Product |
|---|---|
| Also known as | Budesonide solution administered by nebulization |
| Sponsor | Aquilon Pharmaceuticals S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single-dose AQ001S PK Study in Healthy Volunteers (PHASE1)
- Inhaled Steroids for Acute Pharyngitis. (PHASE2, PHASE3)
- Effect of Symbicort on GR Localisation in Asthma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide Inhalant Product CI brief — competitive landscape report
- Budesonide Inhalant Product updates RSS · CI watch RSS
- Aquilon Pharmaceuticals S.A. portfolio CI